Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

Abstract

Objective To investigate the effect of the mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis. Methods A total of 24 adult male C57BL/6J mice were randomly divided into control group, control+SS-31 group, lipopolysaccharide (LPS) group, and LPS+SS-31 group, with 6 mice in each group. The mice were given intraperitoneal injection of LPS (10 mg/kg) to establish a model of sepsis and acute liver injury, followed by intraperitoneal injection of SS-31 (10 mg/kg) for treatment, and the mice in the control group were given intraperitoneal injection of an equal volume of PBS solution, followed by intraperitoneal injection of an equal volume of normal saline. After 12 hours, ELISA was used to measure the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), reactive oxygen species (ROS), superoxide dismutase (SOD), tumor necrosis factor-α (TNFα), interleukin-1β(IL-1β), and interleukin-6 (IL-6), and HE staining was used to observe liver histopathological changes. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results Compared with the LPS group, the LPS+SS-31 group had significant reductions in the serum levels of ALT (140.05±12.22 U/L vs 102.64±8.75 U/L, P < 0.05) and AST (80.22±4.71 U/L vs 69.26±5.37 U/L, P < 0.05) and the levels of ROS (1 030.21±115.87 pg/mL vs 847.84±63.65 pg/mL, P < 0.05), TNFα (767.18±60.60 ng/mL vs 698.89±16.99 ng/mL, P < 0.05), IL-1β (29.97±1.37 ng/mL vs 26.70±3.09 ng/mL, P < 0.05), and IL-6 (59.13±7.09 pg/mL vs 49.29±3.41 pg/mL, P < 0.05) in liver tissue. Compared with the control group based on HE staining, the LPS group showed destruction of hepatic lobular structure, inflammatory cell infiltration, ambiguous intercellular space, and hepatocyte swelling, while the LPS+SS-31 group showed alleviation of inflammatory cell infiltration and hepatocyte swelling. Conclusion The mitochondria-targeted antioxidant SS-31 can reduce the production of ROS, downregulate the highly expressed inflammatory factors in sepsis, and alleviate sepsis-related acute liver injury in mice.
- Liver Diseases,
- Antioxidants,
- Sepsis,
- Mice, Inbred C57BL

FullText(HTML)

References(21)

References

[1]	SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
[2]	FLEISCHMANN C, SCHERAG A, ADHIKARI NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272. DOI: 10.1164/rccm.201504-0781OC.
[3]	WANG L, QIU YL, WANG JS. Advances in research and application of liver organoids[J]. J Clin Hepatol, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047. 王利, 丘倚灵, 王建设. 肝类器官研究及应用进展[J]. 临床肝胆病杂志, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.
[4]	WANG DD, SONG J, ZHANG XL. Research advances in the role of gut microbiota in liver diseases[J]. J Clin Hepatol, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053. 王丹丹, 宋佳, 张晓岚. 肠道菌群在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053.
[5]	XING BM, GUO N, NING HH, et al. Sepsis liver damage and autophagy[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006. 邢博民, 郭娜, 宁海慧, 等. 脓毒症肝损伤与自噬[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006.
[6]	KOBASHI H, TOSHIMORI J, YAMAMOTO K. Sepsis-associated liver injury: Incidence, classification and the clinical significance[J]. Hepatol Res, 2013, 43(3): 255-266. DOI: 10.1111/j.1872-034X.2012.01069.x.
[7]	MARSHALL JC. New translational research provides insights into liver dysfunction in sepsis[J]. PLoS Med, 2012, 9(11): e1001341. DOI: 10.1371/journal.pmed.1001341.
[8]	FUCHS M, SANYAL AJ. Sepsis and cholestasis[J]. Clin Liver Dis, 2008, 12(1): 151-172, ix. DOI: 10.1016/j.cld.2007.11.002.
[9]	CHIAO YA, ZHANG H, SWEETWYNE M, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice[J]. Elife, 2020, 9: e55513. DOI: 10.7554/eLife.55513.
[10]	YANG L, ZHAO K, CALINGASAN NY, et al. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity[J]. Antioxid Redox Signal, 2009, 11(9): 2095-2104. DOI: 10.1089/ars.2009.2445.
[11]	TALBERT EE, SMUDER AJ, MIN K, et al. Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant[J]. J Appl Physiol (1985), 2013, 115(4): 529-538. DOI: 10.1152/japplphysiol.00471.2013.
[12]	SZETO HH, LIU S, SOONG Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury[J]. J Am Soc Nephrol, 2011, 22(6): 1041-1052. DOI: 10.1681/ASN.2010080808.
[13]	WU J, HAO S, SUN XR, et al. Elamipretide (SS-31) ameliorates isoflurane-induced long-term impairments of mitochondrial morphogenesis and cognition in developing rats[J]. Front Cell Neurosci, 2017, 11: 119. DOI: 10.3389/fncel.2017.00119.
[14]	ALLEN ME, PENNINGTON ER, PERRY JB, et al. The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats[J]. Commun Biol, 2020, 3(1): 389. DOI: 10.1038/s42003-020-1101-3.
[15]	ZHANG XT, LIU JZ, LI P, et al. Research progress of mitophagy in sepsis[J]. China Med Herald, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm 张欣桐, 刘景卓, 李盼, 等. 线粒体自噬在脓毒症中的研究进展[J]. 中国医药导报, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm
[16]	SUN XD, YAN YH, ZHANG YT, et al. Effects of Xuebijing injection on oxidative stress and early inflammatory factors in rats with sepsis induced liver injury[J]. Chin J Mod Appl Pharm, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008. 孙雪东, 严一核, 张亦婷, 等. 血必净对脓毒症肝损伤大鼠氧化应激及炎症状态的影响[J]. 中国现代应用药学, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008.
[17]	ZHAO W, XU Z, CAO J, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice[J]. J Neuroinflammation, 2019, 16(1): 230. DOI: 10.1186/s12974-019-1627-9.
[18]	SMUDER AJ, ROBERTS BM, WIGGS MP, et al. Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness[J]. Oncotarget, 2020, 11(38): 3502-3514. DOI: 10.18632/oncotarget.27748.
[19]	HAO ZH, HUANG Y, WANG MR, et al. SS31 ameliorates age-related activation of NF-κB signaling in senile mice model, SAMP8[J]. Oncotarget, 2017, 8(2): 1983-1992. DOI: 10.18632/oncotarget.14077.
[20]	BUTLER J, KHAN MS, ANKER SD, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial[J]. J Card Fail, 2020, 26(5): 429-437. DOI: 10.1016/j.cardfail.2020.02.001.
[21]	KARAA A, HAAS R, GOLDSTEIN A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy[J]. Neurology, 2018, 90(14): e1212-e1221. DOI: 10.1212/WNL.0000000000005255.

Relative Articles

[1]	Liu Li, Jiang YingYi, Liu Jing. Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J]. Journal of Clinical Hepatology, 2020, 36(2): 324-328. doi: 10.3969/j.issn.1001-5256.2020.02.018
[2]	Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
[3]	He YuLan, Sun Lin, Yu HongWei, Meng QingHua. Expression of glucose transporter 2 in liver tissue in patients with hepatogenous diabetes and its significance[J]. Journal of Clinical Hepatology, 2017, 33(3): 512-515. doi: 10.3969/j.issn.1001-5256.2017.03.023
[4]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Clinical features of acute hepatitis B and acute exacerbation of chronic hepatitis B: a comparative study[J]. Journal of Clinical Hepatology, 2016, 32(4): 706-710. doi: 10.3969/j.issn.1001-5256.2016.04.019
[5]	Ruan JianWen, Gao LiJuan, Su RuKai. Clinical features of patients with acute exacerbation of chronic hepatitis B: an analysis of 74 cases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2096-2098. doi: 10.3969/j.issn.1001-5256.2016.11.017
[6]	Xun YunHao, Guo JianChun. Clinical application of traditional Chinese medicine constitution theory in diagnosis and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 644-648. doi: 10.3969/j.issn.1001-5256.2016.04.006
[7]	Zhang ZeTian, Ji HuiFan, Chen Shuai, Li Xu, Yang WenXuan, Zhang GuoShan, Guo XiaoLin. Clinical cure of chronic hepatitis B: a case report[J]. Journal of Clinical Hepatology, 2016, 32(8): 1578-1579. doi: 10.3969/j.issn.1001-5256.2016.08.030
[8]	Zhang WenJie, Chen QiDan, Wan Yu, Deng Hui. Clinical features of male patients with alcoholic liver cirrhosis or hepatitis B cirrhosis complicated by abnormal glucose metabolism[J]. Journal of Clinical Hepatology, 2016, 32(2): 296-300. doi: 10.3969/j.issn.1001-5256.2016.02.020
[9]	Gao YueQiu. Strategy for traditional Chinese medicine prevention and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(1): 35-37. doi: 10.3969/j.issn.1001-5256.2015.01.008
[10]	Peng Hong, Yang Jian, Mai RunZhang, Chen HongTao. Relationship between serum adiponectin level and metabolic indices in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 354-356. doi: 10.3969/j.issn.1001-5256.2014.04.016
[11]	Zhang LiHang, Mao JunLing, Ren HaiFeng, Wang ShanJuan, Zhang Hui, Wan Jian, Liu YanLi, Wang YiFei, Lin YongHui. Relationship between glucose metabolism and hepatic encephalopathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(7): 532-534. doi: 1001-5256 (2013) 07-0532-03
[12]	Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168.
[13]	Zhu QiRong. Nosocomial infections and chronic severe hepatitis B: A clinical study of 162 patients[J]. Journal of Clinical Hepatology, 2012, 28(7): 525-527.
[14]	Li ChunXia, Pan HuaiQiang, Li YanJun, Xu GuangHua, Chen YanPing, Feng JiHong, Wei Hua, Ceng QingLei. One case report of occult hepatitis B infection[J]. Journal of Clinical Hepatology, 2012, 28(1): 66-68.
[15]	Yang Song, Cheng Jun. Interpretation of Chinese guideline on prevention and treatment for chronic hepatitis B (2011version) -status quo and prospect of antiviral therapy[J]. Journal of Clinical Hepatology, 2011, 27(8): 794-795+800.
[16]	Qiu YingFeng, Ding YongGang, Li GuangMing. Analysis of therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment[J]. Journal of Clinical Hepatology, 2011, 27(6): 611-613.
[17]	Huang WeiShen, Yang Li. Predicting scoring system for hepatocellular carcinoma development in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2011, 27(4): 363-364.
[18]	Li Hai, Jia JiDong. Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment[J]. Journal of Clinical Hepatology, 2011, 27(8): 791-793.
[19]	Jin QingLong, Wang ZhongFeng, Yan HongQing, Niu JunQi. The study of the change in creatine kinase in patients with chronic hepatitis B during the antiviral treatment with Telbivudine and Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(2): 143-144+156.
[20]	Li Zhi, Yan HongMei, Xue FaXuan, Wang Tong, Liang Qun, Xu Huan, Li ZhangChun. Short-term clinical effect of telbivudine in the treatment chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(6): 420-421+426.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (1130) PDF downloads(58)

Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

DOI: 10.3969/j.issn.1001-5256.2022.02.025

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

DOI: 10.3969/j.issn.1001-5256.2022.02.025

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content